Serum GFAP and UCHL1: Evaluation of Their Predictive Value for SAH

NCT06581757 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2025-06-15

No results posted yet for this study

Summary

To verify the analytical performance of GFAP and UCH-L1 biomarkers marketed by Abbott Diagnostics and to assess diagnostic accuracy of these biomarkers in predicting subarachnoid haemorrhage

Conditions

  • Subarachnoid Haemorrhage (SAH)

Sponsors & Collaborators

  • The Royal Wolverhampton Hospitals NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Leanne Young · The Royal Wolverhampton NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2025-04-28
Completion
2025-04-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06581757 on ClinicalTrials.gov